Please do not leave this page until complete. This can take a few moments.
Purdue Pharma has asked the federal Food and Drug Administration (FDA) to approve a new, auto-injectable form of one of its drugs to treat opioid overdoses.
The Stamford-based biopharmaceutical company said Monday that the FDA has accepted its filing of a new drug application for the auto-injector delivery form of nalmefene hydrochloride injection.
If the auto-injector is approved, it would be the second treatment containing nalmefene developed by Purdue to specifically treat the growing number of opioid overdoses nationwide, the company said.
The U.S. population is familiar with auto-injectors, which are used to treat severe allergic reactions, Purdue said. If approved by the FDA, the nalmefene auto-injector could be used by healthcare professionals and first responders, as well as by those without medical training, it said.
Purdue President and CEO Dr. Craig Landau said that if the FDA approves the auto-injector, Purdue will “distribute this medication for no profit, as part of our commitment to help abate the opioid crisis.”
Purdue said it currently distributes the drug to medical professionals at no profit to treat opioid overdoses.
The FDA has granted a priority review for the drug application and assigned a goal date of Aug. 7, 2024. Priority review status means that FDA will expedite the process to evaluate a drug that would significantly improve treatment of a serious condition.
Purdue Pharma is the maker of OxyContin, a painkiller that became the subject of numerous lawsuits because the company misled physicians and the public about its highly addictive nature.
In 2020, the company agreed to plead guilty to three federal criminal charges, pay more than $8 billion and close down the company, with its assets used to create a new, government-controlled entity.
Following objections from several states, an amended settlement was reached in 2022, in which the company agreed to pay more than $10 billion.
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments